ATXS Astria Therapeutics Quick Ratio

Astria Therapeutics specializes in developing targeted treatments for severe immune pathologies by investing in advanced antibodies. This historical price chart demonstrates the asset's dynamics, where the current figure is 10.42. The team brings together top immunologists attracted by substantial funding and ambitious goals. Growth prospects are based on edema therapy, the success of which, upon FDA approval, will ensure complete patient loyalty.

Astria Therapeutics (ATXS) is preparing for final clinical trials without currently generating commercial revenue. The quick ratio trend demonstrates the company's ability to fund these developments without relying on illiquid inventories. This metric aggregates cash and accounts receivable, excluding inventory, to assess the capacity to instantaneously settle short-term liabilities. A high value confirms capital resilience in the face of operational expenditures.